Monday, November 9, 2026

USD/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

USD/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.1% for the last 21 sessions. At 08:11 EST on Wednesday, 28 June, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 1.387% up from its 52-week low and 12.812% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.02%, a negative 0.10%, and a positive 0.35%, respectively.

USD/EUR's highest amplitude of average volatility was 0.38% (last week), 0.33% (last month), and 0.35% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd: euro badly needs the economic outlook to improve – socgen. According to FXStreet on Monday, 26 June, "They downplay the significance of the PMI data but for now, EUR/USD continues to track short term rate expectations absurdly closely and the PMI data definitely had an impact on those.", "The EUR/USD danger is that it gets stuck in a tight range for a while longer, but if you can't resist the urge to sell it, we'd recommend doing so against the CAD."
  • Eur/usd to recover from drop following weaker eurozone pmis – MUFG. According to FXStreet on Monday, 26 June, "The drop in EUR/USD by close to 1% on Friday highlighted the greater FX sensitivity to incoming economic data that increasingly influence short-term rate expectations. ", "In that context, the PCE inflation, ISM, NFP and CPI data from the US in the coming weeks will determine whether this EUR/USD drop extends further or recovers."
  • Eur/usd technical analysis: bearish shift still in progress - 26 June 2023. According to DailyForex on Monday, 26 June, "According to the performance on the daily chart below, the general trend of the EUR/USD currency pair has turned bearish. "
  • Eur/usd trades with a mild positive bias just above 1.0900, lacks follow-through. According to FXStreet on Monday, 26 June, "The US Dollar (USD) struggles to capitalize on its recovery gains registered over the past two days, from the lowest level since May 11, and meet with some supply on Monday, which, in turn, is seen lending some support to the EUR/USD pair. ", "Apart from this, the USD price dynamics should produce short-term opportunities around the EUR/USD pair. "
  • Eur/usd forex signal: weak bullish retracement - 26 June 2023. According to DailyForex on Monday, 26 June, "My previous EUR/USD signal on 22nd June was not triggered, as there was no bullish price action when the price first reached the support level identified at $1.0963.", "In my previous analysis of the EUR/USD currency pair last Thursday, I wrote that the technical picture was looking more bullish, but also noted that the price had got close to the big round number at $1.1000 which recently acted as an area of strong resistance. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com